GSN unveils non-invasive prenatal test

The prenatal test is developed utilizing the company’s bioinformatics technology – Parental Support which unites single-nucleotide polymorphism (SNP) technology with bioinformatics algorithms to produce genetic information from small amounts of free-floating fetal DNA found in the mother’s blood.

GSN CEO Matthew Rabinowitz said the application of advanced statistics to non-invasive prenatal testing enables them to deliver information to expecting parents safely and early in the pregnancy.

"We are initiating a large, prospective clinical trial, funded by the National Institutes of Health (NIH), with the maternal fetal medicine centers in the US to evualate the efficacy."